Patients with MS treated with immunosuppressive agents: Across the COVID-19 spectrum

Rev Neurol (Paris). 2020 Jun;176(6):523-525. doi: 10.1016/j.neurol.2020.04.009. Epub 2020 Apr 27.
No abstract available

Publication types

  • Case Reports
  • Letter

MeSH terms

  • Antibodies, Monoclonal, Humanized / therapeutic use
  • Betacoronavirus*
  • COVID-19
  • Coronavirus Infections / diagnosis*
  • Female
  • Fingolimod Hydrochloride / therapeutic use
  • Humans
  • Immunosuppressive Agents / therapeutic use*
  • Middle Aged
  • Multiple Sclerosis, Chronic Progressive / diagnostic imaging
  • Multiple Sclerosis, Chronic Progressive / drug therapy*
  • Multiple Sclerosis, Relapsing-Remitting / drug therapy*
  • Natalizumab / therapeutic use
  • Pandemics
  • Pneumonia, Viral / diagnosis*
  • SARS-CoV-2

Substances

  • Antibodies, Monoclonal, Humanized
  • Immunosuppressive Agents
  • Natalizumab
  • ocrelizumab
  • Fingolimod Hydrochloride